COVID-19/SARS-CoV-2 Program
COVID-19
Pre-clinicalActive
Key Facts
About Spedding Research Solutions
Spedding Research Solutions operates a hybrid business model, combining fee-for-service CRO work in drug formulation and analytics with its own proprietary drug discovery programs. Its most advanced asset is a Phase 2-ready compound with orphan drug designation for ALS (Amyotrophic Lateral Sclerosis), derived from a novel pathway discovery. The company leverages the scientific reputation of its founder, Michael Spedding—a highly cited pharmacologist and Secretary-General of IUPHAR—to organize research consortia and pursue grants, positioning itself at the intersection of service provision and early-stage therapeutic development.
View full company profileTherapeutic Areas
Other COVID-19 Drugs
| Drug | Company | Phase |
|---|---|---|
| COVID-19 Severity Prediction Test | Age Labs | Development |
| PanCytoVir™ (oral probenecid) | TrippBio | Phase 2 |
| ARCoV | Abogen | Approved (EUA) |
| OT-101 | Sapu BioScience | Clinical Trial (Phase not specified) |
| COVID-19 Vaccine (Inactivated) | Kangtai Biological Products | Approved |
| COVID-19 Vaccine (Adenovirus Vector) | Kangtai Biological Products | Approved |
| Idylla SARS-CoV-2 Test | Biocartis | Approved |
| Adjuvanted Cell-Based COVID-19 Vaccine | CSL Seqirus | Marketed |
| Sequential Dialysis Technique | Halberd | Discovery |
| Amubarvimab + Romlusevimab (BRII-196/BRII-198) | Brii Biosciences | Approved |
| COVID-19 Vaccine Testing (for AstraZeneca) | Advaxia Biologics | Approved |
| COVID-19 Vaccine Clinical Batches | Advaxia Biologics | Clinical |